{{Rsnum
|rsid=10459592
|Gene=CYP19A1
|Chromosome=15
|position=51243944
|Orientation=plus
|GMAF=0.4532
|Gene_s=CYP19A1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 40.7 | 39.8 | 19.5
| HCB | 21.3 | 44.9 | 33.8
| JPT | 17.7 | 43.4 | 38.9
| YRI | 9.5 | 38.8 | 51.7
| ASW | 8.8 | 52.6 | 38.6
| CHB | 21.3 | 44.9 | 33.8
| CHD | 22.9 | 48.6 | 28.4
| GIH | 21.8 | 54.5 | 23.8
| LWK | 7.3 | 32.7 | 60.0
| MEX | 27.6 | 48.3 | 24.1
| MKK | 14.7 | 42.3 | 42.9
| TSI | 25.5 | 46.1 | 28.4
| HapMapRevision=28
}}{{PMID Auto
|PMID=21442439
|Title=Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer
}}

{{PMID Auto
|PMID=21319151
|Title=Aromatase (CYP19) promoter gene polymorphism and risk of nonviral hepatitis-related hepatocellular carcinoma.
|OA=1
}}

{{PMID Auto
|PMID=23408108
|Title=Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy.
|OA=1
}}

{{PMID Auto
|PMID=24803183
|Title=Effects of functional genetic polymorphisms in the CYP19A1 gene on prostate cancer risk and survival
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}